BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors.
Veeck
Jurgen
J
Ropero
Santiago
S
Setien
Fernando
F
Gonzalez-Suarez
Eva
E
Osorio
Ana
A
Benitez
Javier
J
Herman
James G
JG
Esteller
Manel
M
D019313:BRCA1 Protein / Q000235:genetics; D024682:BRCA2 Protein / Q000235:genetics; D018899:CpG Islands / Q000235:genetics*; D019175:DNA Methylation; D005260:Female; D018095:Germ-Line Mutation; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D010793:Phthalazines / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use*; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D011065:Poly(ADP-ribose) Polymerases / Q000235:genetics; D011379:Prognosis; D016896:Treatment Outcome
D019313:BRCA1 Protein; D024682:BRCA2 Protein; D010793:Phthalazines; D010879:Piperazines; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D011065:Poly(ADP-ribose) Polymerases; C531550:olaparib